Aduro Biotech Inc (NASDAQ:ADRO) Shorts Declined By 12.97%

April 17, 2018 - By Sonya McDaniel

It was recorded a decrease on Aduro Biotech Inc (NASDAQ:ADRO)’s shorted shares with 12.97%. In April was announced ADRO’s total 6.44M shorted shares by FINRA. Previously was reported down change of 12.97% from 7.40M shares. Previous ADRO’s position will need 9 days to restore. It has 727,900 average volume. 14.18% is Aduro Biotech Inc float short.

The stock increased 4.17% or $0.3 during the last trading session, reaching $7.5.Aduro BioTech, Inc. is downtrending after having declined 11.85% since April 17, 2017. ADRO has 757,494 volume or 18.87% up from normal. ADRO underperformed the S&P500 by 23.40%.

Aduro BioTech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization that transform the treatment of challenging diseases.The firm is worth $607.55 million. It is developing CRS-207, which has completed Phase Ib clinical trials for the treatment of unresectable malignant pleural mesothelioma; that has completed Phase II clinical trials for the treatment of pancreatic cancer; and that is in Phase I/II clinical trials for the treatment of ovarian cancer.Currently it has negative earnings. The firm is also developing ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; ADU-741, which is in Phase I clinical trials for the treatment of prostate cancer; and a product candidate for the treatment of patients with cancers of the gastrointestinal tract.

Aduro BioTech, Inc. (NASDAQ:ADRO) Ratings Coverage

Total analysts of 4 have positions in Aduro BioTech (NASDAQ:ADRO) as follows: 3 rated it a “Buy”, 1 with “Sell” and 0 with “Hold”. The positive are 75%. The firm has $18.0 highest while $8 is the lowest [Target]. The average target $11.38 is 51.73% above the last ($7.5) price. Since October 30, 2017 according to StockzIntelligence Inc Aduro BioTech has 6 analyst reports. On Wednesday, December 13 the rating was maintained by H.C. Wainwright with “Buy”. In Monday, October 30 report Oppenheimer initiated the stock with “Buy” rating. On Wednesday, December 13 the stock has “Outperform” rating by Oppenheimer. On Wednesday, November 1 the rating was maintained by H.C. Wainwright with “Buy”. On Friday, March 2 the firm has “Underperform” rating given by Bank of America.

Aduro BioTech, Inc. (NASDAQ:ADRO) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: